SUMMARY: JC virus (JCV) is a causative agent of progressive multifocal leukoencephalopathy (PML). Methyl CpG binding protein 2 (MeCP2) is a transcriptional control nuclear protein that is abundantly expressed in neurons. We previously observed that the MeCP2 protein is expressed in JCV large T antigen (TAg)-expressing glial cells in PML brains. To investigate the relationship between MeCP2 and JCV TAg, we examined the promoter activity and mRNA and protein expression levels of MeCP2 in JCV TAg-expressing cells. We found that JCV TAg enhances the promoter activity of MeCP2, but does not enhance the mRNA and protein levels of MeCP2. These results suggest that post-transcriptional mechanisms may play a role in MeCP2 expression.
INTRODUCTION
JC virus (JCV) belongs to the family of polyomavirus which includes simian virus 40 (SV40) and BK virus. Progressive multifocal leukoencephalopathy (PML) develops in immunosuppressed patients that suffer from acquired immunodeficiency syndrome (AIDS), hematological malignancies, or have been treated with immunosuppressant agents or monoclonal antibodies such as natalizumab, rituximab, and efalizumab (1, 2) . The number of patients with PML increased after the AIDS pandemic. The introduction of highly active antiretroviral therapy for patients with AIDS-associated PML has changed the prognosis of AIDS. However, it triggers an immune reconstitution inflammatory syndrome, which is caused by pathogens such as JCV. An effective therapeutic strategy for PML has not yet been established (2, 3) .
The histopathological features of the PML brain include multifocal demyelination and the accumulation of enlarged oligodendrocytes and giant bizarre astrocytes. The JCV antigen is usually observed in oligodendrocytes. It was reported that JCV antigen has also been observed in granular cells of the cerebellum and cortical pyramidal neurons (4, 5) .
JCV consists of 5,130 base pair double-stranded circular DNA as its gene and capsid. The JCV genome has a transcriptional control region, early genes, including large T and small t antigens, and late genes, which encode VP1, VP2, VP3, and agnoprotein (6) . Large T antigen (TAg) plays a role in viral DNA replication and the transcription of viral proteins (7) . VP1, the main capsid protein, contributes to capsid formation, while agnoprotein works as a viroporin (8) .
Methyl CpG binding protein 2 (MeCP2) is a nuclear protein encoded in the X chromosome and expressed in a wide variety of human tissues (9) . Previously, MeCP2 was found to bind to single methylated CpG sequences of DNA and function as a transcriptional suppressor (10) (11) (12) . Meanwhile, it was also reported that MeCP2 functions as a transcriptional activator and binds to unmethylated CpG sequences (13, 14) . Other studies demonstrated that MeCP2 is a multifunctional nuclear protein that plays a role in chromatin architecture and the regulation of RNA splicing (9, (15) (16) (17) (18) . Mutations in MeCP2 are the major cause of Rett syndrome, which is an X-linked neurodevelopmental disorder (19) . Duplication of the normal MeCP2 gene also results in neurodevelopmental disorders in males, though it brings about the normal phenotype in females because of the preferential activation of the normal X chromosome (20) . Thus, MeCP2 plays a role in neuronal development and is strictly regulated in its expression (20) (21) (22) (23) . MeCP2 has 2 isoforms, namely, MeCP2A and MeCP2B (24, 25) , and elevated expression of MeCP2A promotes apoptosis in neurons (26) .
Previously, we demonstrated that MeCP2 was expressed in neural glial cells expressing JCV TAg in PML brains by immunohistochemical analysis (27) . In this report, we examined the expression of MeCP2 in the presence of TAg in JCV-permissive IMR-32 cells and other human cell lines.
MATERIALS AND METHODS
Cell lines: Human glioblastoma cell lines U-87 MG, U-138 MG, U-251 MG, U-343 MG, and T98G were purchased from the American Type Culture Collection (Manassas, Va., USA). Human neuroblastoma (SK-N-SH), colon cancer (Caco-2), human embryonic kidney (HEK 293T), breast cancer (MCF7), and epidermoid carcinoma (A431NS) cell lines were obtained from the RIKEN cell bank (Tsukuba, Japan). Neuroblastoma (IMR-32), human embryonic kidney (HEK 293), and uterine cervical cancer (HeLa) cell lines were purchased from the Health Science Research Resource Bank (Osaka, Japan). The neuroblastoma cell line (SH-SY5Y) was purchased from the European Collection of Cell Cultures (Porton Down, Salisbury, UK). Glioblastoma KMG4 (kindly provided by Dr. K. Tabuchi [28] ), SV40-transformed human glial SVG-A cells (kindly provided by Dr. W. J. Atwood [29] ), and colon epithelial HCA 7 cells (30) were also used. All these except for neuroblastoma cell lines were cultured in Dulbecco's minimum essential medium (DMEM) (Nissui, Tokyo, Japan) with 10z fetal bovine serum (FBS), 2 mM Lglutamate, penicillin, and streptomycin (Sigma, St. Louis, Mo., USA). The IMR-32 cells were maintained with additional 0.1 mM non-essential amino acids (NEAA) (Life Technologies, Carlsbad, Calif., USA). SH-SY5Y cells were cultured in 1:1 minimum essential medium (MEM) (Nissui), Ham's nutrient mixture F12 (Life Technologies), 15z FBS, 1 mM sodium pyruvate, 0.1 mM NEAA, penicillin, and streptomycin. The SK-N-SH cells were incubated in MEM alpha (Life Technologies), 10z FBS, penicillin, and streptomycin. All cell lines were incubated in an atmosphere of 5z CO 2 at 379 C.
Gene expression vectors and luciferase reporter vectors: Complementary DNA (cDNA) of JCV TAg was subcloned into the mammalian expression vector pCXN2-Flag, and pCXN2-Flag-JCV-TAg was constructed (31) . We amplified the coding sequence (CDS) of MeCP2 from the plasmid, pcd-MP4, which encoded the CDS of MeCP2 in the pcDNAI (32) , and the insert was cloned into the XhoI and NotI sites of pCMV-Flag (Sigma), designated as pCMV-Flag-MeCP2. Similarly, the CDS of mutated MeCP2 with the replacement of arginine with glycine in its DNA binding domain was amplified from the pEGFP-R111G (33) , and the insert was cloned into the XhoI and NotI sites of pCMV-Flag to construct the pCMV-Flag-MeCP2-R111G vector. The pcd-MP4 and pEGFP-R111G vectors were kindly provided by Dr. S. Kudo (32, 33) .
Following the previous report about the MeCP2 promoter region (34), we amplified the promoter sequence of MeCP2, which is located upstream of MeCP2 exon 1 and extends from nucleotides -1070 to ＋9. For the amplification of the MeCP2 promoter region, we used the full genome extracted from the HEK 293T cells as a template. The cloned sequence of the MeCP2 promoter region was confirmed using the NCBI database (GenBank, AY523575.1). After cloning the sequence, the MeCP2 promoter region was ligated to the NheI and XhoI sites of the pGL3-basic vector (Promega, Madison, Wiss., USA) to generate the pGL3-MeCP2 promoter -1070/＋9 (named -1070/＋9). Using -1070/＋9 as a template, -307/＋9, -257/＋9, -208/＋9, -178/＋9, and -158/＋9 were also constructed. The pGL3-MeCP2 promoters -1070/-209 and -1070/-179 were also synthesized. Information about primers for cloning the MeCP2 promoter regions of -1070/＋9, -307/＋9, and -178/＋9 was kindly provided by Dr. J. Liu (34) . We designed other primers for cloning MeCP2 promoter regions of -257/＋9, -208/＋9, -158/＋9, -1070/-209, and -1070/ -179 based on the NCBI database (GenBank, AY523575.1).
Antibodies: The rabbit polyclonal antibody to MeCP2 (RA7) was kindly provided by Dr. S. Kudo (35) . A mouse monoclonal antibody to SV40 TAg (PAb416) was previously confirmed to cross-react with JCV TAg and was obtained from Calbiochem (San Diego, Calif., USA) (36) . Rabbit polyclonal antibodies to JCV VP1 and JCV agnoprotein were prepared as described previously (36, 37) . The mouse monoclonal antibody to actin was available from Chemicon (Billeria, Mass., USA).
Transfection: The cells were seeded in 24-well collagen-coated plates 18-24 h before transfection. TransIT-2020 (Mirus, Madison, Wis., USA) was used for the transfection of the IMR-32, KMG4, U-87 MG, U-138 MG, U-251 MG, U-343 MG, SVG-A, Caco-2, HCA7, HEK 293, MCF7, and HeLa cell lines. FuGENE HD (Promega) was used for the T98G cells, and Lipofectamine2000 (Life Technologies) was applied for the SH-SY5Y, SK-N-SH, and A431NS cells. We followed the manufacturers' instructions on each transfection.
Viral genome transfection: The full genome of the JCV Mad1 strain was subcloned into pUC19. After amplifying the plasmids, the insert was extracted and selfligated to generate a circular Mad1 genome. For JC viral genome transfection, the IMR-32 cells were seeded in the 24-well collagen plates and transfected with Mad1 using TransIT-2020 following the manufacturers' instructions. One day after transfection, the Mad1 transfected cells were transferred to 6-well collagen plates and cultured for additional 3 days.
Immunoblotting: The cell lysates were made using RIPA buffer (10 mM Tris-HCl [pH 7.5], 1z Triton X-100, 150 mM NaCl, 0.1z sodium dodecyl sulfate [SDS], 1z deoxycholic acid, 5 mM EDTA, 10z glycerol, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, and a complete protease inhibitor mixture [Roche, Basel, Switzerland]). After sonication and centrifugation, lysate proteins (2.5-10.0 mg) were separated by SDS-polyacrylamide gel electrophoresis and examined by immunoblotting using anti-MeCP2 (1:500), anti-SV40 large T (1:1,000), anti-VP1 (1:1,000), anti-agnoprotein (1:2,000), and anti-actin (1:5,000). The immunopositive signals were visualized with horseradish peroxidase-conjugated secondary antibodies (1:5,000; Biosource International, Camarillo, Calif., USA), the Immobilon Western HRP Substrate (Millipore, Bedford, Mass., USA), and VersaDOC (BIO-RAD, Hercules, Calif., USA).
Reverse transcription and real-time polymerase chain reaction (PCR): For RNA extraction, the cell lines were collected and total RNA was extracted using the PureLink RNA Mini Kit (Life Technologies). The total RNA (1 mg) was treated with DNase I (Life Technologies) at Luciferase assay for the MeCP2 promoter. Asterisks indicate the following P values: * P º 0.05, ** P º 0.01, and *** P º 0.001. RLU, relative light unit.
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209 C in 10 ml of reaction mixture. After inactivation of DNase I with 2.5 mM EDTA at 659 C for 10 min, 4 ml of the reaction mixture was used for reverse transcription using a Superscript III (Life Technologies). To verify that the samples were not contaminated with genomic DNA, RNase-free water was added instead of Superscript III reverse transcriptase to at least one negative control sample that was run in parallel.
To confirm the cDNA amplification by conventional PCR, we used 0.25 ml of reaction mixture containing cDNA, TaKara Ex Taq HS (Takara Bio, Otsu, Japan), and gene specific primer sets: MeCP2A, 5?-CTC ACC AGT TCC TGC TTT GAT GT-3? (24) 
The primer specific annealing temperatures were 589 C, 559 C, and 539 C for MeCP2A, MeCP2B, and actin, respectively. The amplified products were run on 2.0z agarose gel and visualized by UV trans illuminator Model M-20 (UVP, Upland, Calif., USA).
After conventional PCR, real-time PCR was performed using 0. (38) . After incubating the mixtures at 959 C for 30 s, the reaction was performed at 959 C for 15 s and then 609 C for 85 s for 40 cycles using the CFX96 Real-Time System (BIO-RAD). The data were normalized to the amount of b-actin mRNA in each cell line (39) , and were expressed as the ratio of mRNA levels in the TAg-transfected cells to the Mock-transfected cells.
Luciferase assay: IMR-32 cells were seeded in 24-well collagen-coated dishes 18-24 h before transfection. The pGL3 reporter vectors and the JCV TAg expression vector, pCXN2-Flag-JCV-TAg, were co-transfected into the cells using TransIT-2020 following the manufacturer's instructions. Forty-eight hours after transfection, the luciferase activity of the cells was measured using a single-luciferase reporter assay system (Promega) according to the manufacturer's protocols. The luminescence intensity was evaluated using a GloMax 96 Microplate Luminometer (Promega). The firefly luciferase activity data are shown as mean values ± SD. The results of each assay were confirmed by three independent transfections.
As several factors are reported to alter the expression of Renilla luciferase (40) , it seemed impossible to use the pRL-TK vector (Promega) as an internal control in our assay. Because the Renilla activity was strongly affected by MeCP2 or TAg expression, we could not normalize each firefly luciferase activity to the Renilla luciferase activity. We evaluated and show only the firefly luciferase activity in this report.
Statistics: Statistical differences between experimental groups were analyzed using Student's t test.
RESULTS

JCV TAg enhances the promoter activity of MeCP2:
We initially examined the effect of JCV TAg on the MeCP2 promoter activity. According to the previous report by Liu and Francke (34), we made various MeCP2 promoter reporter plasmids encoding the promoter sequences 1079 nucleotide (nt) (-1070/＋9), 316 nt (-307/＋9), 266 nt (-257/＋9), 217 nt (-208/ ＋9), 187 nt (-178/＋9), and 167 nt (-158/＋9) in length (Fig. 1) . We measured the firefly luciferase activity in the absence or presence of JCV TAg (Fig. 1) . The promoter activities of all these sequences were enhanced by JCV TAg. The promoter activities of -257/＋9 and -158/＋9 were significantly decreased compared with those of -307/＋9 and -178/＋9, respectively. It was reported that the SP1 binding sites were predicted in the region -178/＋9 (34). Furthermore, SV40 TAg was reported to be related to SP1 and enhance the transcription of target genes (41) .
We next produced promoter plasmids lacking the -208 to ＋9 or -178 to ＋9 regions (Fig. 1) . Both the promoter regions without the 3?-regions marked lower promoter activity than that of the promoter regions without the 5?-regions (-208/＋9).
JCV TAg does not enhance the MeCP2 mRNA level: We next examined whether JCV TAg enhances the MeCP2 mRNA levels in IMR-32 cells. To distinguish between the MeCP2 genome and the cDNA originating from the mRNA of MeCP2, we synthesized primers at exons 2 and 3 and exons 1 and 3 for the MeCP2A and MeCP2B genes, respectively, according to the previous report by Mnatzakanian et al. (24) (Fig. 2A) . The conventional PCR assay demonstrated that there was no significant difference in the mRNA levels of MeCP2A and MeCP2B in the absence or presence of JCV TAg in the IMR-32 cells (Fig. 2B) . We also performed quantitative real-time RT-PCR assay for MeCP2 mRNA in the IMR-32 cells and 12 other additional human cell lines expressed with or without JCV TAg (Figs. 2C and 2D) . The results showed that there was no obvious change in the expression levels of MeCP2A and MeCP2B mRNA from all 13 cell lines in the presence of JCV TAg. Thus, although JCV TAg significantly enhances the MeCP2 promoter activity, TAg does not affect the mRNA levels of MeCP2A and MeCP2B.
JCV TAg does not enhance the MeCP2 protein level: We next examined the MeCP2 protein levels in the presence of JCV TAg. Immunoblot analysis revealed that MeCP2 expression was not enhanced by JCV TAg in the IMR-32 cells, which were susceptible to JCV (Fig.  3A) . We also examined the expression of the MeCP2 protein in the JCV-infected IMR-32 cells, and the ex- MeCP2 expression was not enhanced (Fig. 3A) . Finally, we applied 6 human non-neural cell lines (Caco-2, HCA7, HEK293, MCF7, HeLa, and A431NS) for examination of the JCV TAg effect on MeCP2 expression. MeCP2 expression was not changed in the presence of JCV TAg (Fig. 3B) .
Overexpression of MeCP2 does not enhance the protein levels of JCV TAg, VP1, or agnoprotein: We finally examined the effect of MeCP2 on JCV protein expression. After transfecting the IMR-32 cells with the circular JCV genome, we detected the JCV early protein (TAg) and late proteins (VP1 and agnoprotein) at 4 days post-transfection (Fig. 4) . We co-transfected the IMR-32 cells with the circular JCV genome and MeCP2 wild type (WT) plasmids and examined the JCV protein expression using immunoblotting. We also used a point mutant of MeCP2 in which the arginine at position 111 was replaced by glycine (R111G); the mutant failed to bind to DNA (33) . At 4 days post-transfection, the viral proteins and WT and mutant MeCP2 were detected by immunoblots. The expression levels of endogenous MeCP2 was markedly lower than that of exogenous MeCP2 in the IMR-32 cells (Fig. 4) . The expression levels of TAg, VP1, and agnoprotein did not change in the presence of exogenous MeCP2 (Fig. 4) .
DISCUSSION
MeCP2 is abundantly expressed in neurons and localizes at the nucleus. It has been reported that MeCP2 works as both a transcriptional suppressor and activator (11) (12) (13) (14) , and is essential for neuronal development (19) . Although examinations about the relationship between viral infection and MeCP2 are limited, several investigations have been reported. MeCP2 binds to the latencyassociated nuclear antigen (LANA) of Kaposi sarcomaassociated herpesvirus (42) , and this binding enables MeCP2 and LANA to cooperatively regulate gene expressions in latently infected cells (43) . The herpesvirus saimiri (HVS) ORF73 protein also interacts with MeCP2 and tethers HVS episomes to host chromosomes (44) .
We previously reported that an immunopositive signal of MeCP2 was detected in glial cells expressing JCV TAg in PML brains (27) . In this study, we investigated the relationship between MeCP2 and JCV TAg. We observed that JCV TAg enhanced the promoter activity of MeCP2 and was mainly related to the -307 nt to -257 nt and -178 nt to ＋9 nt region of the MeCP2 promoter region (Fig. 1) . However, JCV TAg did not affect the mRNA and protein expression levels of MeCP2 in the various cell lines analyzed (Figs. 2B, 2C, 2D, 3A , and 3B).
Although MeCP2 was detected in the JCV TAg-expressing glial cells in the PML brains (27), we did not observe enhancement of mRNA and protein levels of MeCP2 in the presence of JCV TAg in vitro. However, JCV TAg exclusively transactivated the promoter activity of MeCP2. Since MeCP2 is a transcriptional control protein, MeCP2 may have an influence on the promoter activity itself. To examine the effect of the MeCP2 protein on the MeCP2 promoter, we measured the MeCP2 promoter activity in the IMR-32 cells transfected with the plasmid encoding MeCP2. The promoter activity of MeCP2 did not change in the IMR-32 cells after exogenous expression of MeCP2 (data not shown). This result suggests that exogenous MeCP2 did not affect the MeCP2 promoter activity in the promoter assay that we used.
The reason why JCV TAg causes the discrepancy between promoter activity and mRNA or protein expression of MeCP2 is uncertain. A similar discrepancy between promoter activities and mRNA or protein expressions was reported about fatty acid binding protein 7 (FABP7) in renal cell carcinoma cell lines (45) . One possibility for the discrepancy in promoter activity and mRNA/protein expression is post-transcriptional modification. Micro RNAs control the level of mRNA after transcription (46) , and rapid degradation of mRNAs or proteins may be another explanation for this discrepancy. The second hypothesis is the epigenetic regulation of MeCP2 expression. MeCP2 promoter methylation and decreased MeCP2 expression have been reported in the study of autistic male brains (47, 48) . The differences in epigenetic factors between PML brains and our system in vitro may explain the discrepancy, and genomic demethylation or acetylation may play an important role.
We clarified that JCV TAg enhances the promoter activity of MeCP2 in vitro. However, the expression levels of MeCP2 mRNA and protein did not change by JCV TAg expression. Although we did not investigate the post-transcriptional modifications or epigenetic conditions of MeCP2, these mechanisms may reveal insights into the discrepancy between the promoter activity and expression levels of MeCP2 mRNA and protein.
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